Multiple SclerosisNCT07535242
Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS
An observational study of Multiple Sclerosis, run by Ondokuz Mayıs University at 1 site in Turkey (Türkiye).
Trial summary
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS. Read more about this study
- Who is it for?
- Ages 18 to 60 years
- Conditions the study is for
- Multiple Sclerosis
- How many people
- 22 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 21 Apr 2026to 5 May 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- No healthy volunteers
- Adult
Study population: Progressive Multiple Sclerosis
Who may be able to join
- Confirmed diagnosis of MS
- Progressive type MS
- Voluntary participation
- Age between 18-60 years
- Cooperative
- EDSS score ≥ 5.5
Who cannot join
- Presence of another neurological disorder
- Change in medication within the last 3 months
- Relapse within the last 3 months
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Ondokuz Mayis University
Samsun, Atakum, 55270
About this study
Official title: Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
- Conditions
- Multiple Sclerosis
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Progressive Multiple Sclerosis | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Expanded Disability Status Scale (EDSS)
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.
Measured: Baseline
Standardized Mini-Mental Test
The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.
Measured: Baseline
Symbol Digit Modalities Test
The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination.
Score range: Typically 0 to ~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function
Measured: Baseline
Multiple Sclerosis Impact Scale (MSIS-29)
Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)
Measured: Baseline
Glial Fibrillary Acidic Protein (GFAP)
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)
Measured: Baseline
Neurofilament Light Chain (NfL)
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Measured: Baseline
Vascular Endothelial Growth Factor (VEGF)
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2026
- Study start21 Apr 2026
- Primary completion30 Apr 2026
- Study completion5 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Ondokuz Mayıs UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 22 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ondokuz Mayıs University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Seda Nur Kemer, Ondokuz Mayıs University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07535242
- Sponsor's protocol ID
- 2025/426
- Status last verified
- Apr 2026
- First submitted
- 3 Apr 2026
- Last updated
- 3 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigation of the Relationship Between Serum GFAP, NfL, and VEGF Levels and Clinical Progression Markers in Progressive Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT07535242
- Acronym / sponsor ID
- 2025/426
- Conditions
- Multiple Sclerosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 22 participants (actual)
- Lead sponsor
- Ondokuz Mayıs UniversityUniversity, hospital or other
- Study start
- 21 Apr 2026 (actual)
- Primary completion
- 30 Apr 2026 (actual)
- Study completion
- 5 May 2026 (actual)
- First posted
- 17 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aimed to investigate whether the biomarkers GFAP, NfL, and VEGF-recently considered important guides for better understanding the pathophysiology of MS-also serve as indicators of clinical progression in MS.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Progressive Multiple Sclerosis | – | – |
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
- Study population
- Progressive Multiple Sclerosis
Key inclusion criteria (6 listed)
- Confirmed diagnosis of MS
- Progressive type MS
- Voluntary participation
- Age between 18-60 years
- Cooperative
Key exclusion criteria (3 listed)
- Presence of another neurological disorder
- Change in medication within the last 3 months
- Relapse within the last 3 months
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Expanded Disability Status Scale (EDSS)
Time frame: Baseline
The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis. Scores range from 0 to 10, in 0.5-point increments, where 0 indicates normal neurological status and 10 indicates death due to multiple sclerosis. The scale is based on the assessment of functional systems and ambulation, with higher scores reflecting greater disability.
Standardized Mini-Mental Test
Time frame: Baseline
The Standardized Mini-Mental Test (MMT/MMSE) score ranges from 0 to 30. Higher scores indicate better cognitive function.
Symbol Digit Modalities Test
Time frame: Baseline
The Symbol Digit Modalities Test (SDMT) is a neuropsychological test used to assess information processing speed, attention, and visual-motor coordination. Score range: Typically 0 to ~110 (number of correct responses in 90 seconds; exact upper limit depends on performance) Higher scores: Indicate better cognitive processing speed and function
Multiple Sclerosis Impact Scale (MSIS-29)
Time frame: Baseline
Score range: 29-145 (each item scored 1-5) Higher scores: Indicate greater impact of MS on daily life (worse physical and psychological status)
Glial Fibrillary Acidic Protein (GFAP)
Time frame: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA)
Neurofilament Light Chain (NfL)
Time frame: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Vascular Endothelial Growth Factor (VEGF)
Time frame: Baseline
This biomarker will be analyzed using the Enzyme-Linked Immunosorbent Assay (ELISA).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Nov 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by Ondokuz Mayıs University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Expanded Disability Status Scale (EDSS) (time frame: Baseline). The study lists 7 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Nov 2026.